Heron Therapeutics (HRTX) Accumulated Expenses (2010 - 2026)

Heron Therapeutics has reported Accumulated Expenses for 17 years, with the latest figure at $6.4 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 0.95% year-over-year to $6.4 million; the trailing twelve-month figure through Mar 2026 stood at $6.4 million (down 0.95% YoY), and the FY2025 full-year result was $9.3 million, up 56.93% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $6.4 million, down from $9.3 million in the prior quarter.
• The five-year high for Accumulated Expenses was $16.3 million in Q2 2022, with the low at $2.1 million in Q4 2022.
• Historically, Accumulated Expenses has averaged $8.5 million across 5 years, with a median of $8.5 million in 2024.
• Annual changes were most pronounced in 2022 — Accumulated Expenses slumped 86.02% — and 2024, when it soared 150.93%.
• Heron Therapeutics' Accumulated Expenses stood at $2.1 million in 2022, then increased by 10.31% to $2.4 million in 2023, then soared by 150.93% to $5.9 million in 2024, then soared by 56.93% to $9.3 million in 2025, then tumbled by 31.07% to $6.4 million in 2026.
• The last three Accumulated Expenses figures came in at $6.4 million (Q1 2026), $9.3 million (Q4 2025), and $8.7 million (Q3 2025), per Business Quant data.